Clinical trials: Macular Disease
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Geographic Atrophy
A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
This is a Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in…
- Trial name
- NCT01229215
- Testing
- FCFD4514S
- Where
- 36 sites in United States, Germany
- Volunteers
- 143 people
- Sponsor
- Genentech, Inc.
Wet Age-related Macular Degeneration
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
GALATIR is a double blind randomized clinical trial comparing efficacy and safety of BCD-021 (bevacizumab) and Lucentis® (ranibizumab) in patients with neovascular wet age-related macular degeneration.
- Trial name
- GALATIR (NCT02036723)
- Testing
- Bevacizumab, Ranibizumab
- Where
- 13 sites in Brazil, Russia
- Sponsor
- Biocad
Neovascular (Wet) Age-related Macular Degeneration
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the…
- Trial name
- NCT06184360
- Where
- United States
- Volunteers
- 2,079 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Geographic Atrophy Secondary to Age-related Macular Degeneration
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)
- Trial name
- NCT07214740
- Testing
- APL-2, Pegcetacoplan
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Macular Degeneration
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.
- Trial name
- NCT04002310
- Testing
- BI 754132
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Myopia, Pathological
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial.
- Trial name
- Myrror (NCT01249664)
- Testing
- VEGF Trap-Eye (BAY86-5321), No Drug
- Where
- 20 sites in Hong Kong, Japan and 3 more
- Volunteers
- 122 people
- Sponsor
- Bayer
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
A study to determine the safety and tolerability of pazopanib eye drops. The study will also determine how the drug is absorbed and metabolized over time.
- Trial name
- NCT01072214
- Testing
- pazopanib
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Age-Related Maculopathy
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
- Trial name
- NCT01577381
- Testing
- RN6G
- Where
- 83 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Pigmentary Maculopathy, Pigmentary Retinopathy
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
The purpose of this study is to evaluate incidence and prevalence rates of the study endpoints (pigmentary maculopathy [PM]/ pigmentary retinopathy [PR]/Any, PM/PR/ pentosan polysulfate sodium [PPS], and PM/PR/Non-PPS) in…
- Conditions
- Pigmentary Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis
- Trial name
- NCT05179460
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Janssen Research & Development, LLC
Geographic Atrophy
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
Safety Assessment of APL-2 in Patients with Geographic Atrophy
- Trial name
- NCT03777332
- Testing
- PEGCETACOPLAN (APL-2)
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC